PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Percentage of patients with clinically relevant symptomatic hypotension

Symptomatic hypotension as reported by the treating physician and defined, but not limited to, severe dizziness or fainting (syncope), lack of concentration, blurred vision, nausea, cold, clammy pale skin, and rapid shallow breathing.

Time frame: Up to 3 years

Percentage of patients with clinically relevant hyperkalemia

Hyperkalemia defined as serum potassium \>5.5 mmol/L \[mEq/L\] after a repeated measure within one week to confirm serum potassium elevation.

Time frame: Up to 3 years

Percentage of patients with clinically relevant renal impairment

Renal impairment is defined as a decrease in eGFR of ≥40% after evaluation (verified at subsequent visit) of potentially reversible causes of renal dysfunction or end stage renal disease or need for dialysis or renal transplantation.

Time frame: Up to 3 years

Percentages of patients having a BNP or NT-proBNP level

Percentage of patients having a BNP before sacubitril/valsartan initiation will be reported; whereas, percentage of patients having NT-proBNP level at baseline and NTproBNP levels throughout the registry will be reported.

Time frame: Up to 3 years

Relationship between changes in NT-proBNP and all-cause mortality